Fresenius, Europe’s biggest publicly traded health-care provider, said Friday that it’s in talks to buy US generic drugmaker Akorn.
While discussions are under way, there’s no certainty of a deal, said Fresenius, a maker of dialysis and medical products. The Germany-based company didn’t elaborate in a statement about the talks and a spokeswoman for Akorn declined to comment.
Akorn could complement Fresenius’s Kabi medicines division, which specializes in intravenous drugs, and accounts for about a fifth of the company’s revenue. Sturm said in February that the company could look at small-to-medium sized acquisitions to build up the business, and didn’t rule out larger deals.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
